MYGN
Signal
Bullish Setup2
Price
1
Move+2.92%Positive session
Volume
1
Volume0.6× avgNormal activity
Technical
1
RSIRSI 56Momentum positive
PRICE
Prev Close
4.80
Open
4.78
Day Range4.78 – 4.97
4.78
4.97
52W Range3.76 – 8.59
3.76
8.59
24% of range
VOLUME & SIZE
Avg Volume
1.7M
FUNDAMENTALS
P/E Ratio
-1.3x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
1.44
Market-like
Quick Read
TrendInsufficient MA data
Momentum
BULLISH
70% gross margin
Valuation
FAIR
P/E not available
Health
WEAK
CR 2.5 · FCF negative
Neutral
Key MetricsTTM
Market Cap$461.93M
Revenue TTM$824.50M
Net Income TTM-$365.90M
Free Cash Flow-$16.20M
Gross Margin69.9%
Net Margin-44.4%
Operating Margin-31.7%
Return on Equity-79.8%
Return on Assets-51.8%
Debt / Equity0.57
Current Ratio2.49
EPS TTM$-3.92

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.

Health Radar
3 strong3 concern
39/100
Liquidity
2.49Strong
Leverage
0.57Strong
Coverage
-24.9xConcern
ROE
-79.8%Concern
ROIC
-41.8%Concern
Cash
$150MStrong
ANALYST COVERAGE33 analysts
HOLD
+21.5%upside to target
Buy
824%
Hold
1958%
Sell
618%
8 Buy (24%)19 Hold (58%)6 Sell (18%)
Full report →
Stock Health
Composite Score
3 of 5 signals bullish
6/10
Technicals
RSI RangeRSI 56 — Bullish momentum
Volume
Volume FlowDistribution — institutional selling
Fundamentals
Last EarningsBeat estimates
Analyst ConsensusHold
~
LiquidityCurrent Ratio 2.49 — healthy liquidity
Upcoming Events
EEarnings ReportMay 6, 2026
Tomorrow
DEx-Dividend DateAug 3, 2026
In 90 days
PDividend PaymentAug 7, 2026
In 94 days
Technicals
Technical SetupBEARISH
Technicals →

Trend

DowntrendGolden Cross · 50D leads 200D by 5.4%

-25.4% vs SMA 50 · -21.4% vs SMA 200

Momentum

RSI56.3
Positive momentum, not extended
MACD-0.48
Below zero — bearish pulse · compressing
Market Position
Price Levels
52W High
$8.59+73.9%
EMA 50
$6.45+30.5%
EMA 200
$6.30+27.6%
Current
$4.94
52W Low
$3.76-23.9%
52-Week RangeNear 52-week low
$3.7624th %ile$8.59
Squeeze SetupVolume-based
Distribution Pressure

Distribution pattern detected. More selling days than accumulation over the past 20 sessions. Not a conducive environment for a squeeze.

20-Day Money Flow
Acc days:1
Dist days:1
Edge:Even
Volume Context
Avg Vol (50D)1.9M
Recent Vol (5D)
1.1M-39%

Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.

Earnings & Analysts

ANALYST ESTIMATES

Consensus of 8 analysts
Analyst revisions:EPS↓ Revised DownRevenue↓ Revised Down

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2025
$822.2M
$821.8M$822.6M
$0.01
±50%
High7
FY2026(current)
$864.1M
$862.6M$865.6M
+5.1%$0.03+256.8%
±50%
High8
FY2027
$910.1M
$906.0M$914.3M
+5.3%$0.13+274.4%
±50%
High8
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryMYGN
Last 8Q
+69.5%avg beat
Beat 6 of 8 quartersMissed 1 Estimates falling
+91%
Q2'24
+509%
Q3'24
+216%
Q4'24
Q1'25
+40%
Q2'25
+600%
Q3'25
-1200%
Q4'25
+300%
Q1'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced height
Analyst Activity
All ratings →
No recent activity
ScotiabankSector Outperform → Sector Perform
May 21
DOWNGRADE
Wells FargoOverweight → Cautious
May 7
DOWNGRADE
Piper SandlerNeutral → Overweight
Mar 12
UPGRADE
Leerink PartnersOutperform → Market Perform
Dec 9
DOWNGRADE
JefferiesUnderperform
Jun 3
DOWNGRADE
Leerink PartnersOutperform
May 8
UPGRADE
SVB LeerinkMarket Perform
May 23
DOWNGRADE
EF HuttonHold
May 23
DOWNGRADE
Credit SuisseNeutral
May 23
DOWNGRADE
Goldman SachsBuy
May 23
UPGRADE
CitigroupNeutral
May 23
DOWNGRADE
Keefe, Bruyette & W…Market Perform
May 23
UPGRADE
Insider Activity
SEC Filings →
4 Buys/0 SellsNet Buying
Raha Samraat S.Dir
$200K
Mar 9
BUY
Phanstiel S. LouiseDir
$224K
Feb 27
BUY
Phanstiel S. LouiseDir
$242K
Feb 26
BUY
Phanstiel S. LouiseDir
$29K
Feb 25
BUY
Financials

INSTITUTIONAL OWNERSHIP

1
Assenagon Asset Management S.A.
1.4M
2
abrdn plc
1.1M
3
Nuveen, LLC
919K
4
Y-Intercept (Hong Kong) Ltd
654K
5
Inspire Investing, LLC
116K
6
HARBOR CAPITAL ADVISORS, INC.
88K
7
PROFUND ADVISORS LLC
53K
8
SG Americas Securities, LLC
52K
News & Activity

MYGN News

20 articles · 4h ago

About

myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com.

Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
R. Bryan Riggsbee
Patrick BurkeExecutive Vice President of Innovation & Strategic Partnerships
Samraat S. RahaPresident, Chief Executive Officer & Director
Matthew ScaloSenior Vice President of Investor Relations
PeersHealth Care(7 companies)
Screen sector →
SymbolPriceDay %Mkt CapP/ERev GrwMarginELO
MYGN
$4.94+0.00%$462M1500
$68.99+0.00%$13.4B1500
$91.17+0.00%$12.0B-4239.0%1500
$518.66+0.96%$11.9B-3008.0%1500
$223.70+8.31%$11.4B+6554.5%-2868.8%1500
$76.39+0.00%$10.7B52.9+2325815.3%-19.7%1500
$182.03+0.00%$10.6B1500
Sector avg+1.33%52.9+1166184.9%-2533.9%1500